Analysts have been eager to weigh in on the Healthcare sector with new ratings on Equillium (EQ – Research Report), Hims & Hers Health (HIMS – Research Report) and Axsome Therapeutics (AXSM – Research Report).
Equillium (EQ)
Leerink Partners analyst Thomas Smith reiterated a Buy rating on Equillium on October 22 and set a price target of $7.00. The company’s shares closed last Tuesday at $0.54, close to its 52-week low of $0.48.
According to TipRanks.com, Smith is a top 100 analyst with an average return of
Currently, the analyst consensus on Equillium is a Strong Buy with an average price target of $6.83.
See today’s best-performing stocks on TipRanks >>
Hims & Hers Health (HIMS)
In a report issued on October 20, Jailendra Singh from Truist Financial maintained a Hold rating on Hims & Hers Health, with a price target of $10.00. The company’s shares closed last Tuesday at $6.26.
According to TipRanks.com, Singh is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Hims & Hers Health with a $12.63 average price target.
Axsome Therapeutics (AXSM)
Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Axsome Therapeutics on October 20 and set a price target of $100.00. The company’s shares closed last Tuesday at $63.72.
According to TipRanks.com, Suvannavejh has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Axsome Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $118.17, implying an 86.9% upside from current levels. In a report issued on October 8, Truist Financial also maintained a Buy rating on the stock with a $150.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
